A secondary analysis of the Southwest Oncology Group S1609 trial found that larger baseline tumor burden correlated with shorter overall survival but not progression-free survival in rare cancer patients treated with nivolumab plus ipilimumab. The study of 722 patients showed tumor burden was independently associated with survival outcomes but not predictive of tumor regression after dual immunotherapy.
Researchers are developing personalized treatment approaches for rare and pediatric cancers using genetic profiling, AI-driven dosing, and 3D-printed medications to improve outcomes while reducing long-term toxicity.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05852522 |
Molecularly Aided Stratification for Tumor Eradication Research |
RECRUITING | |
| NCT04504604 |
TCF-001 TRACK (Target Rare Cancer Knowledge) Study |
RECRUITING | NA |
| NCT03340506 |
Dabrafenib and/or Trametinib Rollover Study |
RECRUITING | PHASE4 |
| NCT01505400 |
Integrated Molecular Profiling in Advanced Cancers Trial |
ACTIVE_NOT_RECRUITING |
